GlassScriptPhysician profile
Julius A Gasso
NPI 1942232038
$8,250.63
in general payments reported to CMS, 2019-2025
36 companies · $33.72 in 2025
The $33.72 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,241 · 2020: $1,059 · 2021: $875 · 2022: $1,032 · 2023: $1,812 · 2024: $1,199 · 2025: $33.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,044.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,123.93 | 2019-2022 | |
| Abiomed | $961.55 | 2019-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $948.08 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $715.08 | 2019-2024 | Brilinta, Wainua |
| Irhythm Technologies, INC. | $654.46 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $577.58 | 2019-2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $454.65 | 2019-2024 | Lifevest |
| Abbott Laboratories | $394.49 | 2020-2024 | Xience Skypoint, Xience Sierra |
| Janssen Pharmaceuticals, INC | $333.85 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.71 | 2019-2024 | Jardiance |
| Inari Medical, INC. | $261.09 | 2020-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $227.75 | 2019-2024 | Repatha |
| Medtronic, INC. | $172.87 | 2021-2024 | Telescope, Tyrx, Azure Xt Dr Mri Surescan |
| Cardiovascular Systems INC. | $139.89 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.70 | 2021-2023 | Verquvo |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Gasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.